Innate Pharma (NASDAQ:IPHA – Get Free Report) is scheduled to be releasing its earnings data before the market opens on Tuesday, November 14th. Persons interested in listening to the company’s earnings conference call can do so using this link.
Innate Pharma Stock Performance
Shares of NASDAQ:IPHA opened at $2.37 on Friday. The business has a 50 day moving average price of $2.59 and a 200 day moving average price of $2.86. Innate Pharma has a twelve month low of $1.81 and a twelve month high of $3.97.
Hedge Funds Weigh In On Innate Pharma
A number of hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC acquired a new position in shares of Innate Pharma in the 2nd quarter worth approximately $42,000. Balyasny Asset Management LLC acquired a new position in shares of Innate Pharma in the 3rd quarter worth approximately $32,000. Jane Street Group LLC raised its holdings in shares of Innate Pharma by 156.3% in the 1st quarter. Jane Street Group LLC now owns 37,736 shares of the company’s stock worth $127,000 after buying an additional 23,012 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Innate Pharma by 389.8% in the 4th quarter. Millennium Management LLC now owns 71,684 shares of the company’s stock worth $267,000 after buying an additional 57,050 shares in the last quarter. Finally, BlackRock Inc. raised its holdings in shares of Innate Pharma by 27.4% in the 1st quarter. BlackRock Inc. now owns 504,408 shares of the company’s stock worth $1,695,000 after buying an additional 108,335 shares in the last quarter. 0.29% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
About Innate Pharma
Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.
- Five stocks we like better than Innate Pharma
- The How and Why of Investing in Gold Stocks
- MarketBeat Week in Review – 11/6 – 11/10
- 5 Top Rated Dividend Stocks to Consider
- Data giants MongoDB and Snowflake just got upgraded
- Which Wall Street Analysts are the Most Accurate?
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.